Zobrazeno 1 - 3
of 3
pro vyhledávání: '"FJ Alonso-Zazo"'
Autor:
L Rubio-Ruiz, C Martín-Blas, J Sánchez-Rubio, N Ibañez-Heras, T Molina-García, L Martín-Zaragoza, FJ Alonso-Zazo, F Fernández-Fraga
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f136caad879a600877641c8fe19902a8
https://doi.org/10.1136/ejhpharm-2022-eahp.180
https://doi.org/10.1136/ejhpharm-2022-eahp.180
Publikováno v:
Section 5: Patient safety and quality assurance.
Background and importance Several trials have demonstrated the benefit of anti-CDK4/6 inhibitors plus endocrine therapy in oestrogen receptor positive (ER+) advanced breast cancer (aBC), in first or subsequent lines of therapy. Based on clinical tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81123c48d3800054dd39778f32cda6c4
https://doi.org/10.1136/ejhpharm-2021-eahpconf.280
https://doi.org/10.1136/ejhpharm-2021-eahpconf.280
Autor:
Teresa Molina-Garcia, Á Aragón-Díez, JM Rodríguez-Heredia, I Cavada Carranza, J Sánchez-Rubio-Ferrandez, FJ Alonso-Zazo, ME Martínez-Núñez, R Vázquez-Sánchez
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Therapeutic decision-making for biologic-therapies (BT) dose optimisation should be based on optimal disease activity results. The goal of BT optimisation is to guarantee long-term effectiveness and safety, maximising economic savings. Pur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a7c27b24c729ccb99bfa284d921d907
https://doi.org/10.1136/ejhpharm-2019-eahpconf.290
https://doi.org/10.1136/ejhpharm-2019-eahpconf.290